Zealand Pharma A/S (OTCMKTS:ZLDPF) Short Interest Update

Zealand Pharma A/S (OTCMKTS:ZLDPF) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 409,800 shares, an increase of 21.1% from the March 31st total of 338,500 shares. Based on an average daily trading volume, of 4,000 shares, the short-interest ratio is currently 102.5 days.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF stock opened at $86.25 on Tuesday. Zealand Pharma A/S has a 52-week low of $32.42 and a 52-week high of $111.44. The stock has a market cap of $4.44 billion, a price-to-earnings ratio of -47.39 and a beta of 0.63. The firm’s 50-day moving average is $92.94 and its 200-day moving average is $67.65.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.08). Zealand Pharma A/S had a negative return on equity of 49.78% and a negative net margin of 203.99%. The business had revenue of $3.35 million for the quarter, compared to analyst estimates of $1.97 million. Sell-side analysts predict that Zealand Pharma A/S will post -2.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, BTIG Research assumed coverage on shares of Zealand Pharma A/S in a research report on Thursday, March 7th. They set a “buy” rating on the stock.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.